POMDOCTOR Ltd
About POMDOCTOR Ltd
Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of its revenue is derived from the Pharmaceutical supply chain segment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $57.2M
- Total assets
- $15.4M
- Market cap
- $13.3M
- Operating margin
- 13.4%
- Net margin
- 6.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $5.0B
- Operating expenses
- $4.3B
- Operating income
- $673.0M
- Income tax
- $129.0M
- Net income
- $327.0M
- EPS (basic)
- $1.29
- EPS (diluted)
- $1.29
Balance sheet
- Total assets
- $16.3B
- Current assets
- $1.2B
- Total liabilities
- $11.7B
- Current liabilities
- $2.3B
- Shareholders’ equity
- $4.4B
Cash flow
- Operating cash flow
- $939.0M
- Investing cash flow
- -$1.2B
- Financing cash flow
- $233.0M
- Net cash flow
- $11.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $13.3M
- P/E ratio
- 0.1
- EPS (diluted)
- $1.29
- Dividend yield
- 981.82%
- Shares outstanding
- 120.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 8, 2025
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Revenue declined 15% from FY2011 to FY2015.
- Trading 98% below its 52-week high.
- Pays a dividend yielding about 981.82% annually.
- Valued at a price-to-earnings (P/E) ratio of 0.1.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review POMDOCTOR Ltd.
Write a review
News about POMDOCTOR Ltd
News & sentiment via Polygon.io
